1. Protective T cell transplants through microencapsulation

Funding code: 0311594

A joint research project funded by the BMBF (Federal Ministry of Education and Research) for the establishment of a supplemental therapy in bone marrow transplantation through protective T cells that are supposed to be generated through microencapsulation. The focus is on minimization of adenoviral infections during the posttranslation phase.

Project partners:

DRFZ, Berlin
RKI, Berlin  
Charité, Berlin
Fresenius, Bad Homburg    
EuroFerm, Erlangen
Institut für BVT, Erlangen
GenExpress, Berlin

Within the joint project it was GenExpress's job to develop a molecular quality control on the basis of a T cell-specific cDNA chip as well as generate suitable antigens - in terms of recom-bination - for the T cell stimulation.

Already available human gene fragments which are suitable for the creation of tissue-specific chips were selected and the collection was expanded by the genes that were additionally required for specification.

An expression system designed by GenExpress served as platform for the recombinant antigens to be produced. Specifically for the particular clinical requirements GenExpress estab-lished a procedure for the generation of the immunodominant antigen.

Cloning of huAdV genes and gene regions for expression in the procaryotic system, expression and down-stream processing huAdV antigens.

The stimulation of donor material with the antigen generated by GenExpress allows the generation of a sufficient volume of adenovirus-specific CD-4 cells so that they allow clinical application.

The most important result of the joint research is that it was possible to successfully develop or establish, respectively, the T cell isolation and expansion as well as the virus monitoring. In addition to the known potential antigens we were able to identify another protein which shows antigenic properties.
The developed procedure allows the original objective of performing a clinical study regarding proof of the positive influence of protective T cell transplants. The first phase of the clinical trial was started in 2006 within the framework of DFG funding (Deutsche Forschungsgemeinschaft, German Research Foundation).



You can now find updated descriptions and price examples of our services.


Positive controls for your PCR: You can now find a selection of our product portfolio in the

Standards-sample-list (169 KB)


Our privacy policy has been updated in accordance with the new EU General Data Protection Regulation (EU GDPR) >>>


The new certificate

ISO 9001-2015 is now available. Go here for download.


In November 2017 GenExpress successfully passed the recertification audit in compliance with ISO 9001:2015.


Reconstruction of QMS ISO 9001 from 2008 to 2015 


GenExpress is celebration its 20th anniversary at the historic "Malzfabrik Berlin"


Completion of joint research profect BIGRUDI  >>read


GenExpress website now also available in English.


In December 2010 GenExpress successfully passed the recertification audit in compliance with ISO 9001:2008. The new certificates are available for download.


GenExpress launches new website.


Successful conclusion of the EU-funded USDEP project.  continue >>